BibSonomy publications for /user/kanefendt/antagonistsBibSonomypublrss/user/kanefendt/antagonistsBibSonomy RSS feed for /user/kanefendt/antagonists2012-02-17T01:20:21+01:00- Sunitinib induced hypertension, thrombotic microangiopathy and reversible posterior leukencephalopathy syndromehttp://www.bibsonomy.org/bibtex/2f4e6a5de4f2b9e413dbb8109656c7786/kanefendtkanefendt2010-02-05T11:28:39+01:00& A Aged Agents Antineoplastic Endothelial Factor Female Growth Humans Hypertension Indoles Middle Neurotoxicity Purpura Pyrroles Receptor-2 Syndromes Thrombocytopenic Thrombotic Vascular adverse antagonists chemically effects etiology induced inhibitors <span class="authorEditorList"><a href="/author/Kapiteijn">E. Kapiteijn</a>, <a href="/author/Brand">A. Brand</a>, <a href="/author/Kroep">J. Kroep</a>, and <a href="/author/Gelderblom">H. Gelderblom</a> </span><em>Ann.Oncol.</em> <em>18(10):1745-1747</em> (<em>2007</em>)
- Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalizationhttp://www.bibsonomy.org/bibtex/2143cacfb64ea0a7986d0ab5e71479dba/kanefendtkanefendt2010-02-05T11:28:39+01:00& Angiogenesis Animals Blood Endothelial Factors Growth Humans Inhibitors Laboratories Neoplasms Neovascularization Pathologic Research Vascular Vessels antagonists blood cells drug inhibitors pathology supply therapeutic therapy use <span class="authorEditorList"><a href="/author/Fukumura">D. Fukumura</a>, and <a href="/author/Jain">R. K. Jain</a> </span><em>Microvasc.Res.</em> <em>74(2-3):72-84</em> (<em>2007</em>)
- Vascular endothelial cell-specific NF-kappaB suppression attenuates hypertension-induced renal damagehttp://www.bibsonomy.org/bibtex/2fe9b6da17080b89b77fd623f65128cf0/kanefendtkanefendt2010-02-05T11:28:39+01:00& Adhesion Albuminuria Angiotensin Animals Atherosclerosis B Blood C57BL Cardiovascular Cell Cells Chain Chloride Cultured Dietary Diseases Endothelial Ester Expression Factor-alpha Fusion Gene Humans Hypertension I-kappa II III Inbred Inflammation Intercellular Kidney Methyl Mice Models Molecule-1 NF-kappa NG-Nitroarginine Necrosis Nephritis Nitric Organ Oxide Polymerase Pressure Proteins Reaction Receptor Recombinant Regulation Research Reverse Signal Sodium Specificity Synthase TIE-1 Transcriptase Transduction Transgenic Tumor Type Vascular antagonists biosynthesis blood cells complications control etiology genetics inhibitors metabolism physiology physiopathology prevention protein toxicity <span class="authorEditorList"><a href="/author/Henke">N. Henke</a>, <a href="/author/Schmidt-Ullrich">R. Schmidt-Ullrich</a>, <a href="/author/Dechend">R. Dechend</a>, <a href="/author/Park">J. K. Park</a>, <a href="/author/Qadri">F. Qadri</a>, <a href="/author/Wellner">M. Wellner</a>, <a href="/author/Obst">M. Obst</a>, <a href="/author/Gross">V. Gross</a>, <a href="/author/Dietz">R. Dietz</a>, <a href="/author/Luft">F. C. Luft</a>, <a href="/author/Scheidereit">C. Scheidereit</a>, and <a href="/author/Muller">D. N. Muller</a> </span><em>Circ.Res.</em> <em>101(3):268-276</em> (<em>2007</em>)
- Vascular endothelial growth factor receptor 3 is involved in tumor angiogenesis and growthhttp://www.bibsonomy.org/bibtex/21d3ba1cc74ddebe211f5e063d1db007f/kanefendtkanefendt2010-02-05T11:28:39+01:00& Animals Antibodies Antitumor Assays BALB Binding C Cell D Endothelial Factor Growth Human Humans Immunohistochemistry Inbred Ligands Mice Model Monoclonal Neoplasms Neovascularization Nude Pathologic Processes Receptor-3 Research Vascular Xenograft analysis antagonists blood immunology inhibitors metabolism pharmacology supply therapy <span class="authorEditorList"><a href="/author/Laakkonen">P. Laakkonen</a>, <a href="/author/Waltari">M. Waltari</a>, <a href="/author/Holopainen">T. Holopainen</a>, <a href="/author/Takahashi">T. Takahashi</a>, <a href="/author/Pytowski">B. Pytowski</a>, <a href="/author/Steiner">P. Steiner</a>, <a href="/author/Hicklin">D. Hicklin</a>, <a href="/author/Persaud">K. Persaud</a>, <a href="/author/Tonra">J. R. Tonra</a>, <a href="/author/Witte">L. Witte</a>, and <a href="/author/Alitalo">K. Alitalo</a> </span><em>Cancer Res.</em> <em>67(2):593-599</em> (<em>2007</em>)
- Cardiotoxicity associated with tyrosine kinase inhibitor sunitinibhttp://www.bibsonomy.org/bibtex/2506ad4630500172729537a9ce24caf9c/kanefendtkanefendt2010-02-05T11:28:39+01:00& Aged Agents Animals Antineoplastic Arteries Artery Blood Carcinoma Coronary Disease Failure Female Gastrointestinal Heart Humans Hypertension Indoles Kinase Kinases Male Mice Middle Multicenter Pressure Protein-Tyrosine Pyrroles Rats Research Retrospective Safety Stroke Stromal Studies Topic Tumors Tyrosine Volume adverse antagonists as blood chemically drug effects induced inhibitors methods therapeutic therapy toxicity use <span class="authorEditorList"><a href="/author/Chu">T. F. Chu</a>, <a href="/author/Rupnick">M. A. Rupnick</a>, <a href="/author/Kerkela">R. Kerkela</a>, <a href="/author/Dallabrida">S. M. Dallabrida</a>, <a href="/author/Zurakowski">D. Zurakowski</a>, <a href="/author/Nguyen">L. Nguyen</a>, <a href="/author/Woulfe">K. Woulfe</a>, <a href="/author/Pravda">E. Pravda</a>, <a href="/author/Cassiola">F. Cassiola</a>, <a href="/author/Desai">J. Desai</a>, <a href="/author/George">S. George</a>, <a href="/author/Morgan">J. A. Morgan</a>, <a href="/author/Harris">D. M. Harris</a>, <a href="/author/Ismail">N. S. Ismail</a>, <a href="/author/Chen">J. H. Chen</a>, <a href="/author/Schoen">F. J. Schoen</a>, <a href="/author/van den Abbeele">A. D. van den Abbeele</a>, <a href="/author/Demetri">G. D. Demetri</a>, <a href="/author/Force">T. Force</a>, and <a href="/author/Chen">M. H. Chen</a> </span><em>Lancet</em> <em>370(9604):2011-2019</em> (<em>2007</em>)
- Surrogate predictive biomarkers for response to anti-EGFR agents: state of the art and challengeshttp://www.bibsonomy.org/bibtex/277bee5565bfa32594d200c2c9fedca93/kanefendtkanefendt2010-02-05T11:28:39+01:00& Antibodies Biological Carcinoma Dosage Drug Epidermal Factor Gene Growth Human Humans Immunohistochemistry Inhibitors Kinase Kinases Lung Markers Monoclonal Mutation Neoplasm Neoplasms Non-Small-Cell Phosphoproteins Predictive Protein Protein-Tyrosine Proteins Proto-Oncogene Quinazolines Receptor Resistance Tests Tyrosine Value analysis antagonists c-akt drug effects erbB-2 erbB-3 genetics identify inhibitors of protein response therapeutic therapy use <span class="authorEditorList"><a href="/author/Cappuzzo">F. Cappuzzo</a>, <a href="/author/Toschi">L. Toschi</a>, <a href="/author/Finocchiaro">G. Finocchiaro</a>, <a href="/author/Ligorio">C. Ligorio</a>, and <a href="/author/Santoro">A. Santoro</a> </span><em>Int.J.Biol.Markers</em> <em>22(1 Suppl 4):S10-S23</em> (<em>2007</em>)
- Severe cardiomyopathy in a patient with renal cell carcinoma after treatment with the novel tyrosine kinase inhibitor sunitinibhttp://www.bibsonomy.org/bibtex/2beabba54bd2d560c3e6e69f70f2777bd/kanefendtkanefendt2010-02-05T11:28:39+01:00& Aged Agents Angiogenesis Antineoplastic Carcinoma Cardiomyopathies Cell Dysfunction Echocardiography Female Humans Illness Index Indoles Inhibitors Kidney Kinase Kinases Left Neoplasms Protein-Tyrosine Pyrroles Renal Severity Tyrosine Ventricular adverse antagonists chemically contraindications drug effects induced inhibitors of therapy <span class="authorEditorList"><a href="/author/Chorianopoulos">E. Chorianopoulos</a>, <a href="/author/Jager">D. Jager</a>, <a href="/author/Katus">H. A. Katus</a>, and <a href="/author/Frey">N. Frey</a> </span><em>Clin.Res.Cardiol.</em> <em>96(11):829-830</em> (<em>2007</em>)
- Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibitionhttp://www.bibsonomy.org/bibtex/2602435fc1730c5168f565863b795701d/kanefendtkanefendt2010-02-05T11:28:39+01:00& Adaptor Antibodies Benzenesulfonates Biological Delivery Diseases Drug Enzyme Heart Human Humans Indoles Inhibitors Kinase Kinases Models Monoclonal Mutation Neoplasms Protein Protein-Tyrosine Proteins Proto-Oncogene Pyridines Pyrroles Quinazolines Research Signal Systems Transducing Tyrosine adverse antagonists c-abl cells chemically development drug effects growth induced inhibitors physiology protein response therapy toxicity <span class="authorEditorList"><a href="/author/Force">T. Force</a>, <a href="/author/Krause">D. S. Krause</a>, and <a href="/author/van Etten">R. A. van Etten</a> </span><em>Nat.Rev.Cancer</em> <em>7(5):332-344</em> (<em>2007</em>)
- Molecular basis for sunitinib efficacy and future clinical developmenthttp://www.bibsonomy.org/bibtex/253e1171b8a15a9f6bacf8979fae3a8bb/kanefendtkanefendt2010-02-05T11:28:39+01:00& A Angiogenesis Animals Carcinoma Clinical Design Drug Endothelial Factor France Growth Humans Indoles Inhibitors Kinase Kinases Neoplasm Neoplasms Protein-Tyrosine Pyrroles Receptors Resistance Topic Trials Tyrosine Vascular adverse antagonists as biosynthesis blood drug effects enzymology inhibitors metabolism pharmacology response supply therapeutic therapy use <span class="authorEditorList"><a href="/author/Faivre">S. Faivre</a>, <a href="/author/Demetri">G. Demetri</a>, <a href="/author/Sargent">W. Sargent</a>, and <a href="/author/Raymond">E. Raymond</a> </span><em>Nat.Rev.Drug Discov.</em> <em>6(9):734-745</em> (<em>2007</em>)
- The clinical toxicity profile of vascular endothelial growth factor VEGF and vascular endothelial growth factor receptor VEGFR targeting angiogenesis inhibitors; a reviewhttp://www.bibsonomy.org/bibtex/2369c88f24f6cf696fc67db33cc272b4f/kanefendtkanefendt2010-02-05T11:28:39+01:00& A Angiogenesis Antibodies Endothelial Factor Growth Humans Inhibitors Kinase Kinases Medical Monoclonal Neoplasms Neovascularization Oncology Pathologic Protein Protein-Tyrosine Receptors Tyrosine Vascular adverse antagonists blood control drug effects inhibitors prevention protein supply therapy toxicity <span class="authorEditorList"><a href="/author/Eskens">F. A. Eskens</a>, and <a href="/author/Verweij">J. Verweij</a> </span><em>Eur.J.Cancer</em> <em>42(18):3127-3139</em> (<em>2006</em>)
- Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directionshttp://www.bibsonomy.org/bibtex/2a983fe521c531b49f0265112de4eeb86/kanefendtkanefendt2010-02-05T11:28:39+01:00& A Angiogenesis Clinical Endothelial Factor Growth Human Humans Inhibitors Kinase Kinases Lung Neoplasms Piperidines Protein Protein-Tyrosine Proteins Quinazolines Receptors Research Safety Topic Trials Tyrosine Vascular antagonists as drug inhibitors metabolism protein therapeutic therapy use <span class="authorEditorList"><a href="/author/Morabito">A. Morabito</a>, <a href="/author/De">Maio E. De</a>, <a href="/author/Di">Maio M. Di</a>, <a href="/author/Normanno">N. Normanno</a>, and <a href="/author/Perrone">F. Perrone</a> </span><em>Oncologist.</em> <em>11(7):753-764</em> (<em>2006</em>)
- Possible molecular mechanisms involved in the toxicity of angiogenesis inhibitionhttp://www.bibsonomy.org/bibtex/2463d0b247e477cd3460c6d76976388b8/kanefendtkanefendt2010-02-05T11:28:39+01:00& A Administration Agents Angiogenesis Antineoplastic Biological Blood Clinical Coagulation Drug Endothelial Factor Function Growth Humans Hypertension Inhibitors Left Models Neoplasm Platelets Research Resistance Schedule Signal Thrombosis Topic Transduction Trials Vascular Ventricular administration adverse antagonists as chemically dosage drug effects etiology induced inhibitors physiology toxicity <span class="authorEditorList"><a href="/author/Verheul">H. M. Verheul</a>, and <a href="/author/Pinedo">H. M. Pinedo</a> </span><em>Nat.Rev.Cancer</em> <em>7(6):475-485</em> (<em>2007</em>)
- Circulating VEGF reduction, response and outcome in advanced colorectal cancer patients treated with cetuximab plus irinotecanhttp://www.bibsonomy.org/bibtex/223511f1ba021049533daca96017b211a/kanefendtkanefendt2010-02-05T11:28:39+01:00& A Adult Aged Antibodies Antineoplastic Biological Camptothecin Chemotherapy Colorectal Combined Disease Endothelial Factor Female Growth Humans Male Markers Medical Middle Monoclonal Neoplasms Oncology Outcome Progression Prospective Protocols Rate Studies Survival Treatment Tumor Vascular administration analogs antagonists blood derivatives dosage drug inhibitors methods mortality response therapeutic therapy trends use <span class="authorEditorList"><a href="/author/Vincenzi">B. Vincenzi</a>, <a href="/author/Santini">D. Santini</a>, <a href="/author/Russo">A. Russo</a>, <a href="/author/Gavasci">M. Gavasci</a>, <a href="/author/Battistoni">F. Battistoni</a>, <a href="/author/Dicuonzo">G. Dicuonzo</a>, <a href="/author/Rocci">L. Rocci</a>, <a href="/author/Rosaria">V. M. Rosaria</a>, <a href="/author/Gebbia">N. Gebbia</a>, and <a href="/author/Tonini">G. Tonini</a> </span><em>Pharmacogenomics.</em> <em>8(4):319-327</em> (<em>2007</em>)
- Doxycycline reduces plasma VEGF-C/sVEGFR-3 and improves pathology in lymphatic filariasishttp://www.bibsonomy.org/bibtex/2ee1fa6cc385bc0da43b7dc0595066e27/kanefendtkanefendt2010-02-05T11:28:39+01:00& Adult Aged Animals C Data Doxycycline Elephantiasis Endothelial Factor Female Filarial Filaricides Growth Humans Hydrocele Intercellular Lymphatic Lymphedema Male Microfilaria Middle Molecular Outcome Parasitemia Peptides Plasma Proteins Receptor-3 Research Sequence Signaling System Testicular Testis Treatment Vascular Vessels Wolbachia and antagonists blood drug effects immunology inhibitors isolation parasitology pathology physiology protein purification therapeutic therapy ultrasonography use <span class="authorEditorList"><a href="/author/Debrah">A. Y. Debrah</a>, <a href="/author/Mand">S. Mand</a>, <a href="/author/Specht">S. Specht</a>, <a href="/author/Marfo-Debrekyei">Y. Marfo-Debrekyei</a>, <a href="/author/Batsa">L. Batsa</a>, <a href="/author/Pfarr">K. Pfarr</a>, <a href="/author/Larbi">J. Larbi</a>, <a href="/author/Lawson">B. Lawson</a>, <a href="/author/Taylor">M. Taylor</a>, <a href="/author/Adjei">O. Adjei</a>, and <a href="/author/Hoerauf">A. Hoerauf</a> </span><em>PLoS.Pathog.</em> <em>2(9):e92</em> (<em>2006</em>)
- Monoclonal antibodies against epidermal growth factor receptor in advanced colorectal carcinoma: clinical efficacy and markers of sensitivityhttp://www.bibsonomy.org/bibtex/22241f0587b827c94106b86f8ce995a2c/kanefendtkanefendt2010-02-05T11:28:39+01:00& Animals Antibodies Biomarkers Carcinoma Colorectal Drug Epidermal Europe Factor Factors Growth Humans Immunologic Ligands Medical Monoclonal Mutation Neoplasm Neoplasms Oncology Pharmacological Phosphorylation Prognosis Receptor Resistance Tyrosine antagonists genetics inhibitors pharmacology response therapeutic therapy use <span class="authorEditorList"><a href="/author/Carcereny">E. Carcereny</a>, and <a href="/author/Maurel">J. Maurel</a> </span><em>Rev.Recent Clin.Trials</em> <em>1(2):113-118</em> (<em>2006</em>)
- Vascular endothelial growth factor expression in monocytes from patients with primary antiphospholipid syndromehttp://www.bibsonomy.org/bibtex/2b235bf38116d96b265bbe73d55a047c1/kanefendtkanefendt2010-02-05T11:28:39+01:00& A Adolescent Adult Aged Antibodies Antiphospholipid Cells Cultured Endothelial Enzyme Expression Factor Female Gene Growth Human Humans Imidazoles Inhibitors Kinase Kinases MAP Male Middle Mitogen-Activated Monocytes Phenotype Protein Pyridines Receptor-1 Regulation Research Signaling Syndrome System Thromboplastin Thrombosis Tyrosine Vascular antagonists biosynthesis cells drug effects inhibitors metabolism p38 pathology pharmacology protein <span class="authorEditorList"><a href="/author/Cuadrado">M. J. Cuadrado</a>, <a href="/author/Buendia">P. Buendia</a>, <a href="/author/Velasco">F. Velasco</a>, <a href="/author/Aguirre">M. A. Aguirre</a>, <a href="/author/Barbarroja">N. Barbarroja</a>, <a href="/author/Torres">L. A. Torres</a>, <a href="/author/Khamashta">M. Khamashta</a>, and <a href="/author/Lopez-Pedrera">C. Lopez-Pedrera</a> </span><em>J.Thromb.Haemost.</em> <em>4(11):2461-2469</em> (<em>2006</em>)
- Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxanehttp://www.bibsonomy.org/bibtex/28296f37e81a4e725fc9d421d2b2defe2/kanefendtkanefendt2010-02-05T11:28:39+01:00& Administration Adult Aged Agents Anthracyclines Antineoplastic Biological Breast Bridged Carcinoma Chemotherapy Combined Compounds Diseases Drug Fatigue Female Gastrointestinal Growth Hematologic Humans Indoles Inflammation Kinase Kinases Markers Middle Neoplasms Oral Plasma Protein-Tyrosine Protocols Pyrroles Rate Schedule Survival Taxoids Tumor Tyrosine administration adverse analysis antagonists blood chemically classification dosage drug effects induced inhibitors methods mortality response secondary therapeutic therapy use <span class="authorEditorList"><a href="/author/Burstein">H. J. Burstein</a>, <a href="/author/Elias">A. D. Elias</a>, <a href="/author/Rugo">H. S. Rugo</a>, <a href="/author/Cobleigh">M. A. Cobleigh</a>, <a href="/author/Wolff">A. C. Wolff</a>, <a href="/author/Eisenberg">P. D. Eisenberg</a>, <a href="/author/Lehman">M. Lehman</a>, <a href="/author/Adams">B. J. Adams</a>, <a href="/author/Bello">C. L. Bello</a>, <a href="/author/Deprimo">S. E. Deprimo</a>, <a href="/author/Baum">C. M. Baum</a>, and <a href="/author/Miller">K. D. Miller</a> </span><em>J Clin Oncol</em> <em>26(11):1810-1816</em> (<em>2008</em>)
- EGFR FISH versus mutation: different tests, different end-pointshttp://www.bibsonomy.org/bibtex/28c7ec5956d78dd1114bd4d35a3eaeafd/kanefendtkanefendt2010-02-05T11:28:39+01:00& Analysis Carcinoma Clinical DNA Drug Epidermal Factor Fluorescence Growth Humans Hybridization In Inhibitors Kinase Lung Mutation Mutational Neoplasm Neoplasms Non-Small-Cell Patient Population Protein Receptor Resistance Selection Situ Topic Trials Tyrosine analysis antagonists as drug genetics identify inhibitors protein response therapeutic therapy use <span class="authorEditorList"><a href="/author/Cappuzzo">F. Cappuzzo</a> </span><em>Lung Cancer</em> <em>60(2):160-165</em> (<em>2008</em>)
- Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumorshttp://www.bibsonomy.org/bibtex/2e1e0093a21e2bfab8ccf40b5087dc8ef/kanefendtkanefendt2010-02-05T11:28:39+01:00& A Administration Adolescent Adult Aged Angiogenesis Biological Contrast Dose Dose-Response Drug Endothelial Factor Factors Fatigue Female Growth Human Humans Hypertension Imaging Inhibitors Kinase Magnetic Male Markers Maximum Media Medical Metastasis Middle Neoplasm Neoplasms Oncology Oral Outcome Pharmacokinetics Plasma Platelet-Derived Protein Proteins Proto-Oncogene Pyridazines Pyridines Receptor Receptor-2 Receptor-3 Relationship Research Resonance Safety Schedule Time Tolerated Treatment Tumor Tyrosine Vascular Young administration adverse antagonists beta blood c-kit diagnostic dosage drug effects enzymology inhibitors methods pathology protein response supply therapy toxicity use <span class="authorEditorList"><a href="/author/Eskens">F. A. Eskens</a>, <a href="/author/Steeghs">N. Steeghs</a>, <a href="/author/Verweij">J. Verweij</a>, <a href="/author/Bloem">J. L. Bloem</a>, <a href="/author/Christensen">O. Christensen</a>, <a href="/author/van">Doorn L. van</a>, <a href="/author/Ouwerkerk">J. Ouwerkerk</a>, <a href="/author/Jonge">M. J. Jonge</a>, <a href="/author/Nortier">J. W. Nortier</a>, <a href="/author/Kraetzschmar">J. Kraetzschmar</a>, <a href="/author/Rajagopalan">P. Rajagopalan</a>, and <a href="/author/Gelderblom">H. Gelderblom</a> </span><em>J.Clin.Oncol.</em> <em>27(25):4169-4176</em> (<em>2009</em>)
- Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitorshttp://www.bibsonomy.org/bibtex/2da3316c6e820f72389299eecdae161d6/kanefendtkanefendt2010-02-05T11:28:39+01:00& 3 50 Angiogenesis Benzenesulfonates Bone Cell Cells Concentration Diseases Endothelial Factor Growth Hematologic Hematopoietic Human Humans Indoles Inhibitors Inhibitory Kinase Line Marrow Myelopoiesis Phosphorylation Platelet-Derived Protein Proteins Proto-Oncogene Pyridines Pyrimidines Pyrroles Receptors Research Specificity Stem Substrate Sulfonamides Tumor Tyrosine Vascular antagonists c-kit chemically drug effects enzymology fms-Like induced inhibitors methods pharmacology protein <span class="authorEditorList"><a href="/author/Kumar">R. Kumar</a>, <a href="/author/Crouthamel">M. C. Crouthamel</a>, <a href="/author/Rominger">D. H. Rominger</a>, <a href="/author/Gontarek">R. R. Gontarek</a>, <a href="/author/Tummino">P. J. Tummino</a>, <a href="/author/Levin">R. A. Levin</a>, and <a href="/author/King">A. G. King</a> </span><em>Br.J.Cancer</em> <em>101(10):1717-1723</em> (<em>2009</em>)